{"id":"influenza-vaccination-with-pcv13","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Injection site erythema"},{"rate":"5-10%","effect":"Injection site swelling"},{"rate":"10-20%","effect":"Injection site pain"},{"rate":"5-10%","effect":"Myalgia"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"1-5%","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PCV13 works by presenting pneumococcal capsular polysaccharides conjugated to a diphtheria toxoid protein carrier, which enhances T-cell dependent immune responses. This approach converts the polysaccharide antigens into T-cell dependent antigens, resulting in improved antibody production, immunological memory, and protection against invasive pneumococcal disease caused by the 13 covered serotypes.","oneSentence":"PCV13 (pneumococcal conjugate vaccine) stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae by conjugating pneumococcal polysaccharide antigens to a protein carrier.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:47.660Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in adults aged 50 years and older"},{"name":"Prevention of invasive pneumococcal disease in children aged 2-59 months"},{"name":"Prevention of pneumococcal otitis media and pneumonia"}]},"trialDetails":[{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT04080531","phase":"PHASE4","title":"Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-10-18","conditions":"Plasma Cell Neoplasm","enrollment":165},{"nctId":"NCT03478254","phase":"","title":"Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).","status":"COMPLETED","sponsor":"Jesús Moreno Fernández","startDate":"2017-12-01","conditions":"Type 1 Diabetes Mellitus","enrollment":300},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT02582047","phase":"PHASE4","title":"Influenza Vaccine and Pneumococcal Vaccine","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2012-10","conditions":"Influenza, Human, Pneumococcal Infections","enrollment":224}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":329,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Influenza vaccination with PCV13","genericName":"Influenza vaccination with PCV13","companyName":"Korea University Guro Hospital","companyId":"korea-university-guro-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"PCV13 (pneumococcal conjugate vaccine) stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae by conjugating pneumococcal polysaccharide antigens to a protein carrier. Used for Prevention of invasive pneumococcal disease in adults aged 50 years and older, Prevention of invasive pneumococcal disease in children aged 2-59 months, Prevention of pneumococcal otitis media and pneumonia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}